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In patients undergoing non-renal transplantation, the favorable outcomes associated with 
calcineurin inhibitors (CNI) have been tempered by the negative impact of CNI nephrotoxicity 
(1). This well described phenomenon has led to the development of end stage renal disease 
(ESRD) as an important complication of non-renal transplantation, and some of these patients 
have gone on to kidney transplantation. A number of centers have reported on the efficacy of 
alemtuzumab induction or preconditioning in patients undergoing kidney transplantation alone (2 
- 10). However, there are no publications describing the utility of alemtuzumab in patients 
undergoing kidney after non-renal transplantation. In this report, we discuss our single center, 
retrospective experience with alemtuzumab induction, and compare it to a previous cohort not 
receiving alemtuzumab. 
Patients and Methods 
Between May 18, 1998 and October 8, 2007, 144 patients underwent kidney after non-
renal transplantation (Table 1). 72 patients received alemtuzumab induction (1 dose of 30 mg IV 
or 0.4 - 0.5 mg/kg in pediatric patients), with 2 peri operative doses of steroids, and simple 
resumption of the pre-kidney transplantation immunosuppressive regimen. 72 patients did not 
receive alemtuzumab; they routinely received additional induction and maintenance steroids, 
higher doses of CNIs, and the addition of an antiproliferative agent (MMF) if they had not been 
on one previously; in addition 3 patients received thymoglobulin and 10 received daclizumab 
induction. There were 133 (92.4%) adults and 11 (7.6%) children. 35 (24.3%) had undergone 
previous heart, 16 (11.1%) lung, 87 (60.4%) liver, and 6 (4.2%) multivisceral transplantation. 
There were 100 (69.4%) deceased donor transplants, with a mean CIT of 24.7 ± 7.9 hours, and 
44 (30.6%) living donor cases; although there was a slightly higher percentage of living donors 
in the alemtuzumab group compared to the no alemtuzumab group, this was not statistically 
different. Alemtuzumab began to be used in our institution in late 2002, so that the follow-up for 
the alemtuzumab patients was shorter, 23.3 ± 15.0 months, than for the no alemtuzumab patients, 
48.1 ± 36.9 months. Once alemtuzumab began to be utilized, almost all patients undergoing 
kidney after non-renal transplantation received it, except for 1 patient who received 
thymoglobulin and 6 patients who received daclizumab. The overall mean follow-up was 35.7 ± 
30.7 months. 
Statistics 
Continuous variables were compared using the t-test with Levene's test employed for 
verifying the assumption of equality of variance. The chi-square test was used to compare 
categorical variables. 
Institutional Oversight 
The data analysis was performed on de-identified data by one of the honest brokers in our 
division, Joseph Donaldson, under the guidelines of the IRB protocol number 0505123. (11) 
Results (Table 2) 
Overall 1 and 3 year actuarial patient survival was 91.5% and 75.3%, and was 93.0% and 
78.9% in the alemtuzumab group and 90.0% and 72.4% in the no alemtuzumab group, 
respectively (p = ns). Overall 1 and 3 year actuarial graft survival was 88.1 % and 71.4%, and 
was 93.0% "and 75.3% in the alemtuzumab group and 83.3% and 68.7% in the no alemtuzumab 
group, respectively (p = 0.051 - Figure 1). The overall mean serum creatinine levels at 1 and 3 
years were 1.4 + 0.7 mg/dl and 1.5 + 0.9 mg/dl, respectively, and were not statistically different 
between the two groups. The incidence of acute rejection was lower in the alemtuzumab group, 
15.3%, than in the no alemtuzumab group, 41.7% (p = 0.0001 - Table 3). The incidence of delayed 
graft function, defined as the need for dialysis during the rust week after transplantation, was lower 
in the alemt.uzumab group, 9.7%, than in the no alemtuzumab group, 25.0% (p = 0.003 - Table 3). 
This difference persisted when only the deceased donor cases were considered: The incidence of 
DGF in the alemtuzumab group was 15.6%, and in the no alemtuzumab group, it was 32.7% 
(p < 0.05). The incidence of viral complications was not different between the two groups. We 
performed several subgroup analyses, looking for any other significant factors, including living 
donation, hepatitis C, diabetes, and the use of extended criteria donor kidneys, which might have 
explained the differences, but none was associated with any outcome differences (data not shown). 
There were 19 HCV + patients undergoing kidney after non-renal transplantation; 7 (4 liver, 
2 heart & 1 lung) received alemtuzumab and 12 (all liver) did not; 10 received no induction, and 2 
received daclizumab. The alemtuzumab cases were transplanted prior to the publication of the 
paper that showed problematic outcomes associated with alemtuzumab and HCV in liver 
transplantation (12). The numbers of cases were in any event too small to analyze. 
The alemtuzumab / no alemtuzumab differences were observed in all non-renal transplant 
subgroups (i.e. heart, lung, liver, multivisceral- data not shown), although statistical significance was 
noted only when the groups were combined. 
Discussion 
Kidney after non-renal transplantation is an uncommon subject for discussion, and the 
approach to immunosuppression is not well defined. In our center, it has accounted for 7.1 % of the 
kidney transplantations that have been performed, with 144/2034 cases in less than 10 years. As the 
kidney is a third party antigen, and as the level of immunosuppression in non-renal transplant 
recipients tends to be relatively low by the time a kidney transplantation needs to be performed, 
some additional immunosuppression needs to be administered to prevent rejection of the kidney. 
The advantage of alemtuzumab induction in this context is that the baseline immunosuppression 
does not need to be changed. This simplifies patient management after transplantation and may 
have the further advantage of being associated with less rejection, less DGF, and slightly better graft 
survival, without any increase in viral complications. It is important to remember, however, that the 
no alemtuzumab group was not randomized and was more of an historic control, so that these 
differences have to be interpreted with caution. 
There are certain settings in kidney after non-renal transplantation where alemtuzumab may 
not necessarily be a good idea. These would include patients who are hepatitis C (HCV) positive 
and have had a previous liver transplant (12), or recently transplanted patients who have received 
heav-ry immunosuppression for the non-renal organ. In these situations, accounting for 6 cases in 
our series, we utilized daclizumab induction 1mg/kg at the time of transplantation and every 2 
weeks for 4 additional doses, with standard tacrolimus/MMF-based immunosuppression, without 
additional maintenance steroids. This seemed anecdotally to be a satisfactory approach in tllese 6 
patients. 
This expenence has important and obvious limitations. It is retrospective, and, as 
mentioned above, not randomized, and the no alemtuzumab group is mostly an historical control. 
Unfortunately, kidney after non-renal transplantation is not performed very often, and a randomized 
trial, either single center or multicenter, while desirable, will not be straightforward to perform. In 
the absence of such a trial, the experience reported here suggests that alemtuzumab induction with 
resumption of pre-kidney transplantation immunosuppression may possibly represent a simple and 
effective regimen in patients undergoing kidney after non-renal transplantation. 
Table 1 
Alemtuzumab No Alemtuzumab 
Overall Group Group 
5/18/1998 - 1/15/2003 - 5/18/1998 -
Time 10/8/2007 10/8/2007 7/21/2007 
N 144 72 72 
Recipient Age_(yrs.) 52.1 +- 16.6 54.1 +- 15.5 50.1 +-17.5 
Donor Age (yrs.) 38.4 +- 16.5 38.0 +- 15.5 38.9 +- 17.6 
Time after Non-renal Tx (yrs.) 8.1 +- 4.7 8.3 +- 5.1 8.0 +- 4.4 
Adult 133 (92.4%) 68 (94.4%) 65 (90.3%) 
Child 11 (7.6%L 4 (5.6%) 7 (9.7%) 
Previous 
Heart 35 (24.3%) 26 (36.1%) 9 (12.5%L 
Lung 16 (11.1 %) 7 (9.7%) 9 (12.5%) 
Liver 87 (60.4%) 37 (51.4%) 50 (69.4%) 
Multivisceral 6 (4.2%) 2 (2.8%) 4 (5.6%1 
Deceased Donor 100 (69.4%) 45 (62.5%) 55 (76.4%) 
Cold Ischemia Time 24.7 +- 7.9 hrs 24.2 +- 7.5 rus 25.1 +- 8.4 hrs 
HCV+ 19 (13%) 7 (10%1 12 (17%)_ 
Living Donor 44 (30.6%) 27 (37.5%) 17 (23.6%) 
PRA 3.3 +- 9.6 2.6 +- 9.7 4.0 +- 9.4 
Table 2 
Alemtuzumab No Alemtuzumab 
Overall Group Group 
Patient 
1 year Survival % 91.5% 93.0% 90.0% 
3 year Survival % 75.3% 78.9% 72.4% 
Graft 
1 vear Survival % 88.1% 93.0% 83.3% 
3 vear Survival % 71.4% 75.3%* 68.7% 
" 
Mean Serum Creatinine 
1 vear 1.4 +- 0.7 mg/dl 1.3 +- 0.5 mg/ dl 1.5 +- 0.8 mg/ dl 
3,year 1.5 +- 0.9 mg/dl 1.3 +- 0.7 mg/ dl 1.6 +- 1.0 mg/ dl 
* p = 0.051 
Table 3 
Overall Alemtuzumab No Alemtuzumab 
Group Group 
Complications 
Acute Rejection 
6 Month 16% 2.8% 29.2%** 
1 Year 20.8% 8.3% 33.3%*** 
Total 28.5% 15.3% 41.7%** 
Delayed Graft Function 17.4% 9.7% 25.0%*** 
Living Donor 0% 0% 0% 
Deceased Donor 25% 15.6% 32.7%**** 
CMV 0% 0% 0% 
PTLD 0.7% 0% 1.4% 
BK Virus 4.2% 4.2% 2.8% 
** P = 0.0001 
*** P = 0.003 
**** P < 0.05 
ci~ure 1 - Graft Survival in Kidney after Non-renal Transplantation 
(alemtuzumab _: no alerntulUmab_ ) 
1.0 
0.9 
0.8 
07 
0.3 
0.::: 
0.1 
00 
- l 
o 3'30 720 10801440 1800 2160 :::520 2880 3:240 3600 
Time After Transplantation (days) 
ACKNOWLEDGMENTS 
InductlonCod.,. 
: 10 
1 
+ O-censored 
1-censored 
The author:; thank Deborah Cood, R.N., BK~KkKI C.C.T.C, C;erri fames, R.N., C.CTC,\ngda 
Barber, R.N., BK~KI c.Cr.(.,.Ianicc Clidewdl, ltN., BSN, C.C.T.C., \Iitzi Barker, R.N., C.CT.C., 
Conk :Dv1ch:atcr~I R.N., H.:'.N., C.C.T.c., Kim ylcvl~rI lC\, Stacy .\ccycdo, R.N., ccre., Nancy 
Egcr, R.N., H.S.N.,\lice Maglione, R.N., .\.D., Mark Paymer, B.S.N., R.N., C.CT.C, i\1aunTn 
Veka:;y, R.N, CCr.C,\my Singh, R.N., B.S.N., C.c:.TJ:., Lori Prothero, R.N., Diane CEFnnor~I 
R.N., M.P.II., Tim Donovan, R.N., c.C.U:., Mcli~~a Choma, RN., C.CR.N., Hollie Lambert R.N., 
\lichcllc Coombs, P .. \.c., Shannon Ross. P .. \ .. C,\shky Myers, P,,\.·c:., and Kris Schonder, 
)lilaI'm!). , for their pfl'()pcratin' and postopnarivc carl' of the patients, and \!elissa (:onndl for 
manuscnpt preparation. 
References 
1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, ArndorferJ, 
Christensen L, Merion RM. Chronic Renal Failure after Transplantation of a Nonrenal 
Organ. N EnglJ Med 2003; 349(10):331-40. 
2. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol2002; 
19(suppl):3. 
3. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-
dose cyclosporine Monotherapy in renal allograft recipients. Lancet 1998; 351: 1701. 
4. Stuart FP, Leventhal JR, Kaufman DB. Alemtuzumab facilitates prednisone free 
immunosuppression in kidney transplant recipients with no early rejection. Am J 
Transplant 2002; 2(suppl):397. 
5. Knechtle SJ, PirschJD, H Fechner] ]r, et al. Campath-1H induction plus rapamycin 
monotherapy for renal transplantation results of a pilot study. Am j Transplant 2003; 
3:722. 
6. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial 
evaluating tl1e humanized CD 52-specific monoclonal antibody alemtuzumab 
(CAMPATH-1H). Transplantation 2003; 76:120. 
7. Shapiro R, Basu A, Tan HP, et al. Kidney transplantation under minimal 
immunosuppression after pretransplant lymphoid depletion with thymoglobulin or 
Campath. J Am Coll Surg 2005; 200:505. 
8. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus 
monotherapy for pediatric kidney transplantation. J Pediatr 2006; 148:813. 
9. Tan HP, Kaczorowski D], Basu A, et al. Living donor renal transplantation using 
alemtuzumab induction and tacrolimus mono therapy. Am J Transp12006; 6:2409. 
10. Shapiro R, Zeevi A, Basu A, Tan HP, Kayler L, Blisard D, Thai N, Girnita A, Randhawa 
P, Gray E, Marcos A, Starzl TE. Alemtuzumab preconditioning with tacrolimus 
monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation 
2008; 85(8):1125-1132. 
11. University of Pittsburgh Institutional Review Board (homepage on the internet) 
Pittsburgh: University ofPittsburgh;2006 (updated 2006 January 17; cited'2006 
February 10). Jurisdiction, Structure, and Responsibilities of the Institutional Review 
Board. Reference Manual for the Use of Human Subjects in Research. Available 
online at http://www.irb.pitt.edu/manuallpreface.pdf 
12. Eghtesad B, FungJJ, Demetris, AJ, Murase N, Ness R, Bass DC, Gray EA, Shakil 0, 
Flynn B, Marcos A, and Starzl TE, Immunosuppression for Liver Transplantation in 
HCV-Infected Patients: Mechanism-Based Principles. Liver Transplantation 2005; 
11(11):1343-52. 
